The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias

International Journal of Clinical Oncology

Volumn 12, Issue 5, 2007, Pages 327-340

  Maekawa, Taira ^a   Ashihara, Eishi ^a   Kimura, Shinya ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

CML; Dasatinib; INNO 406; Nilotinib; SKI 606

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ABELSON KINASE; ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DORAMAPIMOD; HYDROXYUREA; IMATINIB; INNO 406; INTERFERON; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NILOTINIB; NS 187; OLIGODEOXYNUCLEOTIDE DERIVATIVE; ON 012380; ONCOPROTEIN; ORGANIC CATION TRANSPORTER 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RIBONUCLEASE H; SGX 70430; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG RESEARCH; EDEMA; HEADACHE; HUMAN; NEUTROPENIA; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 35348866151     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0699-1     Document Type: Review

References (134)

1. S Faderl M Talpaz Z Estrov 1999 Chronic myelogenous leukemia: biology and therapy Ann Intern Med 131 207 219
2. JM Goldman JV Melo 2003 Chronic myeloid leukemia - advances in biology and new approaches to treatment N Engl J Med 349 1451 1464
3. JD Rowley 1973 A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 290 293
4. N Heisterkamp JR Stephenson J Groffen 1983 Localization of the c-Abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia Nature 306 239 242
5. R Kurzrock JU Gutterman M Talpaz 1988 The molecular genetics of Philadelphia chromosome-positive leukemias N Engl J Med 319 990 998
6. TG Lugo AM Pendergast AJ Muller ON Witte 1990 Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products Science 247 1079 1082
7. CL Sawyers 1999 Chronic myeloid leukemia N Engl J Med 340 1330 1340
8. E Fainstein C Marcelle A Rosner 1987 A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia Nature 330 386 388
9. M Sattler JD Griffin 2003 Molecular mechanisms of transformation by the Bcr-Abl oncogene Semin Hematol 40 4 10
10. H Wada S Mizutani J Nishimura 1995 Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 Bcr-Abl fusion protein Cancer Res 55 3192 3196
11. JV Melo 1996 The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype Blood 88 2375 2384
12. RW Bolin WA Robinson J Sutherland RF Hamman 1982 Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia Cancer 50 1683 1686
13. J Goldman 2003 Management of chronic myeloid leukemia Semin Hematol 40 1 103
14. HM Kantarjian TL Smith S O'Brien 1995 Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service Ann Intern Med 122 254 261
15. JM Goldman 1992 Bone marrow transplantation for chronic myeloid leukaemia Leukemia 6 Suppl 2 22 23
16. S Kimura T Maekawa 2006 Stem cell transplantation for Ph+ leukemias in the imatinib and post-imatinib eras DF Davidson Bone marrow transplantation: new research (review) Nova Science Publishers New York 1 38
17. N Heisterkamp G Jenster J ten Hoeve 1990 Acute leukaemia in bcr/abl transgenic mice Nature 344 251 253
18. GQ Daley RA Van Etten D Baltimore 1990 Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 247 824 830
19. WS Pear JP Miller L Xu 1998 Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow Blood 92 3780 3792
20. DS Krause RA Van Etten 2005 Tyrosine kinases as targets for cancer therapy N Engl J Med 353 172 187
21. T Skorski M Nieborowska-Skorska NC Nicolaides 1994 Suppression of Philadelphia1 leukemia cell growth in mice by Bcr-Abl antisense oligodeoxynucleotide Proc Natl Acad Sci USA 91 4504 4508
22. T Maekawa S Kimura K Hirakawa 1995 Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by Bcr-Abl antisense oligonucleotide phosphorothioates Int J Cancer 62 63 69
23. RA Van Etten 2003 c-Abl regulation: a tail of two lipids Curr Biol 13 R608 R610
24. KM Smith R Yacobi RA Van Etten 2003 Autoinhibition of Bcr-Abl through its SH3 domain Mol Cell 12 27 37
25. E Buchdunger J Zimmermann H Mett 1996 Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 100 104
26. T Schindler W Bornmann P Pellicena 2000 Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 1938 1942
27. C Gambacorti-Passerini CP Le L Mologni 1997 Inhibition of the Abl kinase activity blocks the proliferation of Bcr-Abl+ leukemic cells and induces apoptosis Blood Cells Mol Dis 23 380 394
28. MW Deininger JM Goldman N Lydon 1997 The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of Bcr-Abl-positive cells Blood 90 3691 3698
29. BJ Druker S Tamura E Buchdunger 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561 566
30. BJ Druker 2001 Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia Semin Hematol 38 3 Suppl 8 9 14
31. BJ Druker M Talpaz DJ Resta 2001 Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037
32. K Arnold 2001 After 30 years of laboratory work, a quick approval for STI571 J Natl Cancer Inst 93 13 972
33. SG O'Brien F Guilhot RA Larson 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004
34. JM Goldman JV Melo 2003 Chronic myeloid leukemia - advances in biology and new approaches to treatment N Engl J Med 349 1451 1464
35. BJ Druker F Guilhot SG O'Brien 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417
36. CL Sawyers A Hochhaus E Feldman 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 3530 3539
37. J Cools DJ DeAngelo J Gotlib 2003 A tyrosine kinase created by fusion of the PDGFA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N Engl J Med 348 1201 1214
38. A Pardanani RP Ketterling SR Brockman 2003 CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy Blood 102 3093 3096
39. TR Golub GF Barker M Lovett 1994 Fusion of the PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation Cell 77 307 316
40. M Baccarani G Saglio J Goldman 2006 Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia net Blood 108 1809 1820
41. A Hochhaus P La Rosee 2004 Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance Leukemia 18 1321 1331
42. ME Gorre M Mohammed K Ellwood 2001 Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification Science 293 876 880
43. T Hegedus L Orfi A Seprodi 2002 Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1 Biochim Biophys Acta 1587 318 325
44. H Burger H van Tol M Brok 2005 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of theABCG2 (BcrP) and ABCB1 (MDR1) drug transport pumps Cancer Biol Ther 4 747 752
45. M Kotaki T Motoji M Takanashi 2003 Anti-proliferative effect of the Abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line Cancer Lett 199 61 68
46. NJ Donato JY Wu J Stapley 2003 BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 Blood 101 690 698
47. Y Dai M Rahmani SJ Corey 2004 A Bcr-Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 J Biol Chem 279 34227 34239
48. A Ptasznik Y Nakata A Kalota 2004 Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, Bcr-Abl1(+) leukemia cells Nat Med 10 1187 1189
49. C Gambacorti-Passerini R Barni P le Coutre 2000 Role of alpha1 acid glycoprotein in the in vivo resistance of human Bcr-Abl(+) leukemic cells to the Abl inhibitor STI571 J Natl Cancer Inst 92 1641 1650
50. J Thomas L Wang RE Clark 2004 Active transport of imatinib into and out of cells: implications for drug resistance Blood 104 3739 3745
51. WK Hofmann LC Jones NA Lemp 2002 Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique Bcr-Abl gene mutation Blood 99 1860 1862
52. S Branford Z Rudzki S Walsh 2003 Detection of Bcr-Abl mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in theATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 276 283
53. V Nardi M Azam GQ Daley 2004 Mechanisms and implications of imatinib resistance mutations in Bcr-Abl Curr Opin Hematol 11 35 43
54. M Deininger E Buchdunger BJ Druker 2005 The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2640 2653
55. S Soverini G Martinelli G Rosti 2005 Abl mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia J Clin Oncol 23 4100 4109
56. NP Shah JM Nicoll B Nagar 2002 Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 117 125
57. A Hochhaus 2003 Cytogenetic and molecular mechanisms of resistance to imatinib Semin Hematol 40 Suppl 2 69 79
58. HM Kantarjian M Talpaz F Giles 2006 New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance Ann Intern Med 145 913 923
59. T Schindler W Bornmann P Pellicena 2000 Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 1938 1942
60. CB Gambacorti-Passerini RH Gunby R Piazza 2003 Molecular mechanisms of resistance to imatinib in Philadelphia chromosome-positive leukaemias Lancet Oncol 4 75 85
61. S Soverini G Martinelli G Rosti 2005 Abl mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia J Clin Oncol 23 4100 4109
62. S Soverini G Martinelli M Amabile 2004 Denaturing-HPLC-based assay for detection of Abl mutations in chronic myeloid leukemia patients resistant to Imatinib Clin Chem 50 1205 1213
63. J Cortes F Giles S O'Brien 2003 Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha Blood 102 83 86
64. S O'Brien F Giles M Talpaz 2003 Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase Cancer 98 888 893
65. J Kuroda S Kimura Y Kobayashi 2003 The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate Blood 102 2229 2235
66. H Kantarjian M Talpaz S O'Brien 2004 High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 103 2873 2878
67. C Abram S Courtneidge 2000 Src family tyrosine kinases and growth factor signaling Exp Cell Res 254 1 13
68. Bcr-Abl in myeloid cells Cancer Res 56 3589 3596
69. M Stanglmaier M Warmuth I Kleinlein 2003 The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains Leukemia 17 283 289
70. N Donato J Wu J Stapley 2004 Imatinib mesylate resistance through Bcr-Abl independence in chronic myelogenous leukemia Cancer Res 64 672 677
71. W Hofmann S de Vos D Elashoff 2002 Relation between resistance of Philadelphia-chromosome positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet 359 481 486
72. B Nagar WG Bornmann P Pellicena 2002 Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res 62 4236 4243
73. A Klejman SJ Schreiner M Nieborowska-Skorska 2002 The Src family kinase Hck couples Bcr-Abl to STAT5 activation in myeloid leukemia cells EMBO J 21 5766 5774
74. Y Hu Y Liu S Pelletier 2004 Requirement of Src kinases Lyn, Hck, and Fgr for Bcr-Abl1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia Nat Genet 36 453 461
75. A Ptasznik Y Nakata A Kalota 2004 Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug resistant, Bcr-Abl1(+) leukemia cells Nat Med 10 1187 1189
76. M Talpaz NP Shah H Kantarjian 2006 Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2531 2541
77. NP Shah C Tran FY Lee 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399 401
78. T O'Hare DK Walters EP Stoffregen 2005 In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 4500 4555
79. E Weisberg PW Manley W Breitenstein 2005 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129 141
80. C Gambacorti-Passerini M Gasser S Ahmed 2005 Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies Leukemia 19 1267 1269
81. SW Cowan-Jacob V Guez G Fendrich 2004 Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment Mini Rev Med Chem 4 285 299
82. LJ Lombardo FY Lee P Chen 2004 Discovery of N-(2-chloro-6-methyl-phenyl)- 2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 6658 6661
83. JS Tokarski JA Newitt CY Chang 2006 The structure of Dasatinib (BMS-354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants Cancer Res 66 5790 5797
84. MR Burgess BJ Skaggs NP Shah 2005 Comparative analysis of two clinically active Bcr-Abl kinase inhibitors reveals the role of conformation-specific binding in resistance Proc Natl Acad Sci USA 102 3395 3400
85. S Soverini G Martinelli S Colarossi 2007 Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL Lancet Oncol 8 273 274
86. HM Kantarjian F Giles A Quintas-Cardama 2007 Important therapeutic targets in chronic myelogenous leukemia Clin Cancer Res 13 1089 1097
87. A Hochhaus H Kantarjian M Baccarini 2006 Dasatinib efficacy and safety in patients with chronic phase CML resistant or intolerant to imatinib: results of the CA180013 "START-C" phase II study (abstract 6508) J Clin Oncol 24 339s
88. F Guilhot J Apperley DW Kim 2007 Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase Blood 109 4143 4150
89. J Cortes D Kim P Rosti 2006 Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): results of the CA180006 "START-B" study (abstract 6529) J Clin Oncol 24 344s
90. S Coutre G Martinelli H Dombret 2006 Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): the CA180015 'START-L' study (abstract 6528) J Clin Oncol 24 344s
91. N Shah P Rousselot R Pasquini 2006 Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial (abstract 6507) J Clin Oncol 24 338s
92. A Quintas-Cardama H Kantarjian D Jones 2007 Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure Blood 109 497 499
93. HA Bradeen CA Eide T O'Hare 2006 Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood 108 2332 2338
94. + leukemias Blood 109 2112 2120
95. M Azam V Nardi WC Shakespeare 2006 Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance Proc Natl Acad Sci U S A 103 9244 9249
96. T O'Hare R Pollock EP Stoffregen 2004 Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML Blood 104 2532 2539
97. JM Golas K Arndt C Etienne 2003 SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice Cancer Res 63 375 381
98. http://www.clinicaltrials.gov/ct/show/NCT00261846?order=2. Accessed 10 May 2007
99. http://www.clinicaltrials.gov/ct/show/NCT00195260?order=1. Accessed 11 Jul 2007
100. JM Golas J Lucas C Etienne 2005 SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models Cancer Res 65 5358 5364
101. M Sattler MG Mohi YB Pride 2002 Critical role for Gab2 in transformation by Bcr-Abl Cancer Cell 1 479 492
102. E Weisberg PW Manley W Breitenstein 2005 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129 141
103. T O'Hare DK Walters EP Stoffregen 2005 In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 4500 4555
104. M Golemovic S Verstovsek F Giles 2005 AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia Clin Cancer Res 11 4941 4947
105. H Kantarjian F Giles L Wunderle 2006 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2542 2551
106. E Jabbour F Giles J Cortes 2006 Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP) J Clin Oncol 24 6591s
107. S Kimura H Naito H Segawa 2005 NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood 106 3948 3954
108. T Asaki Y Sugiyama T Hamamoto 2006 Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors Bioorg Med Chem Lett 16 1421 1425
109. H Naito S Kimura Y Nakaya 2006 In vivo inhibitory effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on the proliferation of leukemic cells harbouring Abl kinase domain mutations Leuk Res 30 1443 1446
110. + leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity Blood 109 306 314
111. AR Craig HM Kantarjian JE Cortes 2007 A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib (abstract 7046) J Clin Oncol 25 18s
112. K Gumireddy SJ Baker SC Cosenza 2005 A non-ATP-competitive inhibitor of Bcr-Abl overrides imatinib resistance Proc Natl Acad Sci U S A 102 1992 1997
113. R Giet C Prigent 1999 Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases J Cell Sci 112 3591 3601
114. EA Harrington D Bebbington J Moore 2004 VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat Med 10 262 267
115. MA Young NP Shah LH Chao 2006 Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680 Cancer Res 66 1007 1014
116. FJ Giles J Cortes D Jones 2007 MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation Blood 109 500 502
117. http://www.clinicaltrials.gov/ct/show/NCT00405054?order=1. Accessed 1 Aug 2007
118. TA Carter LM Wodicka NP Shah 2005 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proc Natl Acad Sci USA 102 11011 11016
119. T O'Hare BJ Druker 2005 BIRB-796 is not an effective ABL(T315I) inhibitor Nat Biotechnol 23 1209 1210
120. Burley SK (2005) Application of FAST™ fragment-based lead discovery and structure-guided design to discovery of small molecule inhibitors of BCR-ABL tyrosine kinase active against T315I imanitib-resistant mutant (abstract 698[) Blood 106:11 (Suppl) 206a
121. DJ Barnes JV Melo 2006 Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia Cell Cycle 5 2862 2866
122. HG Jorgensen TL Holyoake 2001 A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia Hematol Oncol 19 89 106
123. M Dean T Fojo S Bates 2005 Tumour stem cells and drug resistance Nat Rev Cancer 5 275 284
124. T Holyoake X Jiang C Eaves 1999 Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia Blood 94 2056 2064
125. T Maekawa D Metcalf 1991 Suppression of clonogenicity of human leukemic cells by recombinant hemopoietic factors T Miyazaki F Takaku H Uchino Myelodysplastic syndrome and cytokines Elsevier Amsterdam 101 110
126. SM Graham HG Jorgensen E Allan 2002 Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 319 325
127. MS Holtz ML Slovak F Zhang 2002 Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation Blood 99 3792 3800
128. R Bhatia M Holtz N Niu 2003 Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 4701 4707
129. M Copland A Hamilton LJ Elrick 2006 Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction Blood 107 4532 4539
130. HG Jorgensen EK Allan NE Jordanides 2007 Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells Blood 109 4016 4019
131. F Michor TP Hughes Y Iwasa 2005 Dynamics of chronic myeloid leukaemia Nature 435 1267 1270
132. NL Komarova D Wodarz 2005 Drug resistance in cancer: principles of emergence and prevention Proc Natl Acad Sci USA 102 9714 9719
133. T O'Hare DK Walters EP Stoffregen 2005 Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib Clin Cancer Res 11 19 Pt 1 6987 6993
134. DL White VA Saunders SR Quinn 2007 Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs Blood 109 3609 3610